Stocks Health care TOVX

NYSE · Health care

Theriva Biologics, Inc. (TOVX)

It posted a net loss of $13.1M. In fiscal 2025 capital spending exceeded operating cash flow by $16.7M. At June 30, 2026 it held $11.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.

Watch TOVX in 60 seconds

Follow TOVX

Free, no password. An email when TOVX files with the SEC.

Key facts about Theriva Biologics, Inc.

Net worth

Theriva Biologics, Inc. has a market value (market cap) of $7.4M at the latest share price, and shareholders' equity of $12.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Cash flow

In fiscal 2025 operations used $16.7M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

Next earnings report

Theriva Biologics, Inc.'s next report is expected around November 17, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

What Theriva Biologics, Inc. does

Theriva Biologics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker TOVX.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Theriva Biologics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 24, 2026
   Employee stock plan registration S-8
2. August 11, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.07 versus -$1.93.
3. August 11, 2026
   Quarterly results 8-K
4. August 6, 2026
   Investor disclosure 8-K
5. August 4, 2026
   Executive or director change 8-K
6. July 7, 2026
   Investor disclosure 8-K
7. June 29, 2026
   Proxy statement DEF 14A
8. June 29, 2026
   Annual report to shareholders ARS
9. June 18, 2026
   Preliminary proxy statement PRE 14A
10. June 11, 2026
    Investor disclosure 8-K

Recent insider filings (Forms 3, 4 and 144): 7, the latest on January 6, 2026. Insider transactions on SEC

Insider trades

What the people running Theriva Biologics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns TOVX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Empery Asset Management, LP 4.99% (October 21, 2025); CVI Investments, Inc. 4.9% (February 7, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about TOVX

What does Theriva Biologics, Inc. do?

Theriva Biologics, Inc. is a company in the Health care sector, listed on NYSE as TOVX. Its shares trade on NYSE under the ticker TOVX.

What is Theriva Biologics, Inc.'s net worth?

Theriva Biologics, Inc. has a market value (market cap) of $7.4M at the latest share price, and shareholders' equity of $12.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Theriva Biologics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $13.1M.

When did Theriva Biologics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the employee stock plan registration from August 24, 2026.

When is Theriva Biologics, Inc.'s next earnings report?

Theriva Biologics, Inc.'s next report is expected around November 17, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

Compare TOVX with

Compare TOVX with any company

Follow TOVX

Get an email when Theriva Biologics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow TOVX

Free, no password. An email when TOVX files with the SEC.

Where the numbers come from

Financial figures are the values Theriva Biologics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.